REGENXBIO
RGNX
NASDAQ
IPO2015
about RGNX
REGENXBIO develops viral vector-based gene therapies targeting rare diseases.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $9.61 | $11.50 | $9.51 | $678.86M | 3.60M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.20 | n/a | 18.84 | -176.27% | -208.32% | 0% |